glp-faq
All FAQs
FAQgeneral

When will retatrutide be approved by the FDA?

Retatrutide is in Phase 3 trials as of 2026. FDA approval is unlikely before 2027 at the earliest, and 2028 is a more realistic target based on typical review timelines.

Updated May 15, 2026 · 3 min read

A woman sitting on a couch talking to a man
Photo by CDC on Unsplash

Retatrutide will not be FDA-approved in 2026. Phase 3 trials are underway, but regulatory approval requires Phase 3 data, a Biologics License Application (BLA) submission, and FDA review — a process that typically runs 18–30 months from the end of the trial. 2027 is the earliest plausible window; 2028 is more likely based on current trial timelines.

Where Phase 3 Currently Stands

Eli Lilly's Phase 3 program for retatrutide (internally called TRIUMPH) was initiated following strong Phase 2 results published in the New England Journal of Medicine in 2023. The trials are evaluating retatrutide across:

  • Adults with obesity (BMI ≥30) or overweight with comorbidities — the primary weight management indication
  • Adults with type 2 diabetes — comparable to the path tirzepatide took with SURPASS
  • Potentially a cardiovascular outcomes trial, though timing for CVOT is longer

Phase 3 trials for obesity drugs typically run 72–104 weeks to capture sufficient weight loss data and longer-term safety signals. If Lilly's Phase 3 trials began in late 2024, the earliest primary data readouts would arrive in late 2026 or 2027.

No Phase 3 primary results have been announced as of this writing.

The Path From Data to Approval

Even after a successful Phase 3 readout, the regulatory pipeline takes time:

  1. BLA preparation: compiling the full package of Phase 1, 2, and 3 data, manufacturing information, labeling proposals. Typically 6–12 months post-trial.
  2. FDA review: the standard review period for a Priority Review designation is 6 months from BLA acceptance; Standard Review is 10–12 months. Obesity drugs with significant unmet need often receive Priority Review.
  3. Advisory committee meetings: the FDA may convene an external advisory panel to review the data before making a determination.
  4. Labeling negotiations: even after approval in principle, final approved labeling can take additional weeks or months.

Historical benchmarks from this drug class:

  • Semaglutide 2.4 mg (Wegovy): Phase 3 completed 2021, FDA approved June 2021 — unusually fast due to Priority Review and the agency's familiarity with the molecule from Ozempic
  • Tirzepatide (Mounjaro for T2D): Phase 3 completed 2021, approved May 2022
  • Tirzepatide (Zepbound for obesity): approved November 2023, roughly 18 months after Mounjaro

A realistic retatrutide timeline, assuming successful Phase 3 data in late 2026:

  • BLA submission: mid-2027
  • FDA decision: late 2027 to 2028

This is an optimistic path. Delays in Phase 3 enrollment, safety signals requiring additional study, or manufacturing scale-up issues (Lilly has previously experienced capacity constraints with tirzepatide) could push the timeline further.

What About Compounded Retatrutide?

Short answer: it doesn't exist in any legitimate form.

Compounding pharmacies can produce copies of FDA-approved drugs that are on the shortage list (under specific regulatory conditions). Retatrutide is not FDA-approved at all, which means:

  • Compounding it would be manufacturing an unapproved drug
  • It is not on any FDA shortage list (there's no approved version to be in shortage)
  • Any vendor selling "retatrutide" for self-administration is selling an unregulated substance of unknown identity and purity

This is a different situation from compounded semaglutide or tirzepatide, which were produced during documented shortage periods under FDA enforcement discretion. Retatrutide does not fall under that framework.

What to Do While Waiting

If you're interested in retatrutide because current GLP-1 options haven't produced the results you hoped for, the realistic options are:

  • Clinical trial enrollment: ClinicalTrials.gov lists active TRIUMPH trial sites. Participants in Phase 3 receive the drug (or placebo) at no cost and receive more frequent clinical monitoring than typical care.
  • Optimize on a current agent: many people who "plateaued" on semaglutide haven't yet tried tirzepatide, which produces meaningfully greater weight loss at maximum doses in trial data.
  • Wait for data: the Phase 2 results are genuinely promising, but they're Phase 2. Phase 3 may look different.

The evidence here is preliminary enough that locking in retatrutide as your plan while it's pre-approval isn't a strategy — it's a holding pattern with significant uncertainty attached.